As of Feb 03, 2025, ResMed Inc. Intrinsic Value is $193.0. This suggests it may be overvalued by 19.8% compared to its current price of around $240.6.
As of Feb 03, 2025, ResMed Inc.'s Discounted Cash Flow (DCF) valuation estimates its share price at $142.9. This suggests it may be overvalued by 40.6% to its current price of around $240.6, using a discount rate of 7.6% and terminal growth rate of 3.0%.
ResMed Inc. is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $193.0, compared to a market price of around $240.6. This suggests a potential overvaluation of 19.8%.